94 related articles for article (PubMed ID: 23364341)
1. Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation.
Zouein FA; Zgheib C; Hamza S; Fuseler JW; Hall JE; Soljancic A; Lopez-Ruiz A; Kurdi M; Booz GW
Hypertens Res; 2013 Jun; 36(6):496-503. PubMed ID: 23364341
[TBL] [Abstract][Full Text] [Related]
2. The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.
Beak JY; Kang HS; Huang W; Myers PH; Bowles DE; Jetten AM; Jensen BC
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H186-H200. PubMed ID: 30387679
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice.
Peng H; Yang XP; Carretero OA; Nakagawa P; D'Ambrosio M; Leung P; Xu J; Peterson EL; González GE; Harding P; Rhaleb NE
Exp Physiol; 2011 Aug; 96(8):756-64. PubMed ID: 21602297
[TBL] [Abstract][Full Text] [Related]
4. TIGAR Deficiency Blunts Angiotensin-II-Induced Cardiac Hypertrophy in Mice.
He X; Williams QA; Cantrell AC; Besanson J; Zeng H; Chen JX
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397106
[TBL] [Abstract][Full Text] [Related]
5. Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling.
Yang N; Zou C; Luo W; Xu D; Wang M; Wang Y; Wu G; Shan P; Liang G
Phytother Res; 2023 Feb; 37(2):578-591. PubMed ID: 36178264
[TBL] [Abstract][Full Text] [Related]
6. I-
Cao Y; Li L; Liu Y; Chen G; Tao Z; Wang R; Chen W
Oxid Med Cell Longev; 2021; 2021():6429197. PubMed ID: 33628362
[TBL] [Abstract][Full Text] [Related]
7. Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia.
Vemuri V; Kratholm N; Nagarajan D; Cathey D; Abdelbaset-Ismail A; Tan Y; Straughn A; Cai L; Huang J; Kakar SS
Cells; 2024 May; 13(9):. PubMed ID: 38727319
[TBL] [Abstract][Full Text] [Related]
8. Deficit of glucocorticoid-induced leucine zipper amplifies angiotensin-induced cardiomyocyte hypertrophy and diastolic dysfunction.
Cappetta D; De Angelis A; Flamini S; Cozzolino A; Bereshchenko O; Ronchetti S; Cianflone E; Gagliardi A; Ricci E; Rafaniello C; Rossi F; Riccardi C; Berrino L; Bruscoli S; Urbanek K
J Cell Mol Med; 2021 Jan; 25(1):217-228. PubMed ID: 33247627
[TBL] [Abstract][Full Text] [Related]
9. OTUD6A in tubular epithelial cells mediates angiotensin II-induced kidney injury by targeting STAT3.
Sun X; Chen S; Zhao Y; Wu T; Zhao Z; Luo W; Han J; Fang Z; Ye B; Cao G; Huang S; Liang G
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C400-C413. PubMed ID: 38105755
[TBL] [Abstract][Full Text] [Related]
10. 20(S)-ginsenoside Rh2 inhibits angiotensin-2 mediated cardiac remodeling and inflammation associated with suppression of the JNK/AP-1 pathway.
Yu T; Xu J; Wang Q; Han X; Tu Y; Wang Y; Luo W; Wang M; Liang G
Biomed Pharmacother; 2023 Dec; 169():115880. PubMed ID: 37956481
[TBL] [Abstract][Full Text] [Related]
11. Myocardial Hypertrophy and Compensatory Increase in Systolic Function in a Mouse Model of Oxidative Stress.
Varshney R; Ranjit R; Chiao YA; Kinter M; Ahn B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670798
[TBL] [Abstract][Full Text] [Related]
12. Cardiomyocyte-specific deletion of TLR4 attenuates angiotensin II-induced hypertension and cardiac remodeling.
Theobald D; Nair AR; Sriramula S; Francis J
Front Cardiovasc Med; 2023; 10():1074700. PubMed ID: 37034342
[TBL] [Abstract][Full Text] [Related]
13. Early-life exposure to lead changes cardiac development and compromises long-term cardiac function.
Liu Q; Xu C; Jin J; Li W; Liang J; Zhou S; Weng Z; Zhou Y; Liao X; Gu A
Sci Total Environ; 2023 Dec; 904():166667. PubMed ID: 37652374
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Stat3 activity attenuates HIV-induced kidney injury.
Feng X; Lu TC; Chuang PY; Fang W; Ratnam K; Xiong H; Ouyang X; Shen Y; Levy DE; Hyink D; Klotman M; D'Agati V; Iyengar R; Klotman PE; He JC
J Am Soc Nephrol; 2009 Oct; 20(10):2138-46. PubMed ID: 19608706
[TBL] [Abstract][Full Text] [Related]
15. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.
Machackova J; Barta J; Dhalla NS
Can J Cardiol; 2006 Sep; 22(11):953-68. PubMed ID: 16971981
[TBL] [Abstract][Full Text] [Related]
16. Insulin augments angiotensin II-induced myocardial fibrosis via the MEK/STAT3 pathway.
Cao N; Wang H
Heliyon; 2023 Dec; 9(12):e22860. PubMed ID: 38125490
[TBL] [Abstract][Full Text] [Related]
17. Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.
Song L; Chen X; Swanson TA; LaViolette B; Pang J; Cunio T; Nagle MW; Asano S; Hales K; Shipstone A; Sobon H; Al-Harthy SD; Ahn Y; Kreuser S; Robertson A; Ritenour C; Voigt F; Boucher M; Sun F; Sessa WC; Roth Flach RJ
Elife; 2020 Nov; 9():. PubMed ID: 33200983
[TBL] [Abstract][Full Text] [Related]
18. STAT3-driven hematopoiesis and lymphopoiesis abnormalities are dependent on serine phosphorylation.
Balic JJ; White CL; Dawson R; Gough D; McCormack MP; Jenkins BJ
Cytokine; 2020 Mar; 130():155059. PubMed ID: 32200265
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking the Cβ subunit of PKA are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction.
Enns LC; Bible KL; Emond MJ; Ladiges WC
BMC Res Notes; 2010 Nov; 3():307. PubMed ID: 21080942
[TBL] [Abstract][Full Text] [Related]
20. Correction for: miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis.
Li F; Li SS; Chen H; Zhao JZ; Hao J; Liu JM; Zu XG; Cui W
Aging (Albany NY); 2023 Oct; 15(20):11692-11693. PubMed ID: 37903553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
